Qiagen NV | QIA - Selling And Administration Expenses


Qiagen NV reported $142.33M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 424K 23K Jun/2026
argenx SE USD 598M 181M Sep/2026
Avita Medical AUD 19.54M 516K Jun/2026
Dianthus Therapeutics USD 13.56M 1.09M Jun/2026
Ionis Pharmaceuticals USD 154M 23.92M Sep/2026
IQVIA Holdings USD 569M 5M Sep/2026
Moderna USD 282M 66M Sep/2026
Organon & Co USD 407M 27M Sep/2026
Qiagen NV USD 142.33M 60K Jun/2026
Revvity USD 275.33M 3.25M Sep/2026
Tectonic Therapeutic USD 6.17M 260K Jun/2026
Viatris USD 950.8M 183.7M Sep/2026
Xeris Pharmaceuticals USD 61.04M 7.89M Jun/2026